Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline programs to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley e

Income seekers can't go wrong with these companies.

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-m

These two are on the Dividend Kings list.

Low-cost index funds can be a ticket to prosperity for everyday investors.

Ahead of CPI data and the Fed's rate decision, defensive stocks McDonald's, Johnson & Johnson, Walmart, Berkshire Hathaway, and NextEra Energy offer stability and dividends amid market uncertainty.

If interest rates rise, writing a prescription today for the State Street Health Care Select Sector SPDR ETF is a smart idea.

Intuitive Surgical's flywheel isn't selling new surgical robots, its selling parts and services to support the ones it has already sold.

One of J&J's investments stands head-and-shoulders above the rest.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Looking for a dividend stock you can sleep well owning? Here's why Johnson & Johnson could be the long-term healthcare anchor your portfolio needs.